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SYNOPSIS
There are two cyclo-oxygenase enzymes: COX-1 regulates
physiological function in the gut and kidney, while
COX-2 is induced in inflammation and repair.
Selective COX-2 inhibitors are now available. In early
clinical trials their efficacy in arthritis was equivalent to
that of less selective non-steroidal anti-inflammatory drugs
and they had a significantly lower incidence of
gastrointestinal adverse effects. Larger and longer outcome
studies are awaited to address issues such as a possible
delaying effect of COX-2 inhibitors on ulcer healing and
the potential for adverse cardiovascular effects.
Index words: anti-inflammatory drugs, arthritis, adverse
effects.
(Aust Prescr 2000;23:30–2)
Introduction
The inhibition of prostaglandin synthesis by aspirin and other
non-steroidal anti-inflammatory drugs (NSAIDs) was first
described over 20 years ago.1 The NSAIDs are now one of the
most commonly used medications worldwide, with annual
sales in the order of US$13 billion. These drugs are frequently
used for the management of musculoskeletal diseases and for
other causes of acute and chronic pain. Despite their clear
efficacy in the management of inflammation, NSAIDs are a
significant cause of adverse events, particularly gastrointestinal
ulceration2 and altered renal function.
The enzyme responsible for prostaglandin synthesis is cyclo-
oxygenase (COX). Following the observation that
dexamethasone inhibits the increase in COX activity induced
in macrophages, but has no effect on basal production of
prostaglandins, it was proposed that there were two enzymes,
COX-1 and COX-2.3 The COX-1 enzyme seems to have
primarily a ‘housekeeping’ role, subserving normal
physiological function in the gut and kidney and being involved
with platelet activation. The COX-2 enzyme is induced during
inflammation and tissue repair and also has significant
physiological roles to play in reproduction and in renal function
(Fig. 1). The molecular function and protein structures of the
COX isoforms were rapidly identified. This led to the
development of a number of selective COX-2 inhibitors.
These drugs should provide the same efficacy as the non-
selective NSAIDs with fewer gastrointestinal adverse reactions.
There is a huge potential market for these drugs. In the first few
months following its launch in the USA sales of one COX-2
inhibitor exceeded those of sildenafil.
Assessment of COX-2 selectivity
There is a wide variety of assays to assess COX-1 and
COX-2 selectivity.4 This has led to confusion in the reporting
of the relative effects of some of the new selective inhibitors
depending on which assay system is used. The Human Whole
Blood Assay is probably the best available currently to assess
inhibition of COX-1 and COX-2.
This assay has recently been modified slightly as the William
Harvey Human Modified Whole Blood Assay (WHMA). A
Fig. 1
Cyclo-oxygenase enzymes.
COX-1 is involved in normal physiological functions
including the production of protective prostaglandins in
the stomach. COX-2 is induced by inflammation.
Both enzymes are inhibited by non-steroidal
anti-inflammatory drugs (NSAIDs). COX-2 inhibitors
have little effect on COX-1 activity and so do not inhibit
prostaglandin synthesis.
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wide range of COX-2/COX-1 ratios has been reported for
currently available and experimental NSAIDs.5 These data
are summarised in Fig. 2 with rofecoxib being greater than
50-fold COX-2 selective, and celecoxib being 5-to-50 fold
COX-2 selective. Diclofenac, sulindac and piroxicam have
less than 5-fold COX-2 selectivity.
Measuring COX inhibition in gastric mucosa by using gastric
biopsies may also provide important additional information.
Although these investigations may define COX selectivity,
they do not necessarily imply that COX-2 selective drugs will
have improved safety profiles – this can only be shown by
randomised controlled clinical trials.
Clinical studies
When comparing the adverse effects of COX-2 inhibitors
with those of NSAIDs appropriate doses must be used. It is
essential to compare doses which have similar efficacy.
Although the new COX-2 inhibitors had significantly lower
incidences of gastric injury in the short term, 12-month
anti-inflammatory and gastrointestinal outcome studies against
standard NSAIDs are required to fully assess their efficacy
and adverse effects.
Celecoxib
In single dose studies celecoxib (100 mg and 400 mg) was
superior to placebo and as effective as aspirin (650 mg) in
relieving the pain of dental extraction. Phase II and III studies
of up to six months in doses of 100–400 mg/day for osteoarthritis
and 200–800 mg/day for rheumatoid arthritis showed
equivalence to naproxen 1 g daily or diclofenac 150 mg daily
in terms of efficacy. In normal volunteers, endoscopic studies
with celecoxib 100 mg or 200 mg twice daily for seven days
revealed levels of gastric mucosal injury similar to those of
placebo. Larger three-6 or six-month studies showed the
incidence of ulcers was similar to placebo and significantly
reduced compared to naproxen and diclofenac.
Rofecoxib
Rofecoxib has a long half-life and is suitable for once-daily
dosing in osteoarthritis and rheumatoid arthritis. A single dose
of 50 mg is superior to placebo and equivalent to ibuprofen
400 mg or naproxen 550 mg for relieving acute pain after
dental extraction. Gastric mucosal injury at seven days is
similar to placebo, but less than ibuprofen 2.4 g daily or aspirin
2.6 g daily. A recent analysis of eight double-blind randomised
controlled trials, including two one-year efficacy studies
versus diclofenac 150 mg daily, in over 5000 osteoarthritis
patients has reported a significantly lower 12-month
cumulative incidence of perforations, ulcers and upper
gastrointestinal tract bleeding with rofecoxib than with other
NSAIDs (1.3% versus 1.8%).7
Future directions
Significant interest has now been shown in the role that
inflammation (driven by COX-2) plays in conditions such as
Alzheimer’s disease and colonic carcinoma.8 COX-2 is
certainly induced around the inflammatory plaques seen widely
throughout the central nervous system in Alzheimer’s disease,
and COX-2 expression is upregulated dramatically in colonic
carcinoma. Epidemiological data support the argument that
patients taking NSAIDs have a lower incidence and a slower
rate of progression of Alzheimer’s disease. NSAIDs also
reduce the growth rate of colonic polyps in humans9 and the
incidence of colonic tumours in animals.
The selective COX-2 inhibitors seem to have similar effects,
increasing blood pressure and reducing renal function, as the
non-selective COX inhibitors. Selective COX-2 inhibitors
should not be given to people with aspirin sensitivity as there
are no published studies to show that this is safe for these
patients. Although there is some theoretical concern relating
to the potential for an increased risk of thrombosis with
 COX-2 inhibitors this does not seem to have been borne out
by studies to date. Larger and longer-term studies are
however required to answer these and other issues such as
whether or not ulcer healing might be impaired by a selective
COX-2 inhibitor. Since these drugs have the potential for
widespread use in the community it is important that cost-
effectiveness studies are carried out, although it would seem
that the selective COX-2 inhibitors may be cost-effective for
those patients at high risk of ulcer complications.10
Fig. 2
Selectivity of COX-2 inhibitors and non-steroidal
anti-inflammatory drugs5 given as log inhibitory
concentration (IC80) ratio. The ‘0’ line indicates
equipotency.
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Conclusion
The efficacy of the new drugs is not greater than that of the
NSAIDs. However, if the current large outcome studies of
celecoxib and rofecoxib confirm the reduced gastrointestinal
toxicity then these drugs will increase the options for the
treatment of arthritis.
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(A summary of all clinical trials of the COX-2 inhibitors
appears on the National Prescribing Service web site at
www.nps.org.au under Topics)
Brand premiums
A number of years ago, benchmark pricing was introduced
to the Pharmaceutical Benefits Schedule, whereby a drug
company would be allowed to introduce a brand surcharge
for their particular product. My understanding of the
operation of this scheme was that it would follow the
guidelines of the Australian Competition and Consumer
Commission with respect to collusive pricing and price fixing.
This would not appear to be the case, as many products today
are obviously manufactured by the same company, their logo
and name appearing on both the generic and premium-priced
product (despite having a ‘different’ manufacturing code on
the Pharmaceutical Benefits Schedule). An explanation of
how brand price premiums are allowed, and calculated, would
be appreciated.
Michael D. Rumpff
Pharmacist
Sale, Vic.
The Secretary of the Pharmaceutical Benefits Pricing Authority
comments:
The Brand Premium Policy was introduced in December 1990
to reduce price controls where possible by allowing
pharmaceutical suppliers to set their own price on multi-
branded and therapeutically interchangeable brands listed on
the Pharmaceutical Benefits Scheme, provided one brand was
available at the subsidised price. This also encourages the
development of the generic pharmaceutical industry in
Australia.
Under the policy, suppliers of multi-branded items are able to
set their own prices at a level they think the market will bear.
At the same time, prescribers, pharmacists and patients can
decide whether it is necessary to pay more for a particular
brand when a cheaper equivalent and therapeutically
interchangeable brand is available.
As the brand premium is not a government charge, it does not
count towards a patient’s safety net. The premium arises from
the supplier’s price setting and the majority of it goes to the
supplier, with wholesalers and pharmacists receiving a
percentage.
Under the competitive environment, it is up to the sponsor of
the product to set the price at which it sells its brand. The
government only sets the subsidised price. The pricing freedom
that applies is similar to that of many other commodities such
as food, clothing and cosmetics.
As of February 2000 there were 236 benefit items with a brand
premium that could be therapeutically interchanged. The
average brand premium was $1.45 and premiums ranged from
$0.23 to $43.28.
Your questions to the PBAC
Self-test questions
The following statements are either true or false
(answers on page 47)
1. The efficacy of COX-2 inhibitors is greater than the
efficacy of non-steroidal anti-inflammatory drugs.
2. It is currently unknown if an inhibitor with high
selectivity for COX-2 will be safer than a less
selective COX-2 inhibitor.
